A compound of formula I, or a pharmaceutically acceptable salt or ester thereof,
wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.
BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS
申请人:Novartis AG
公开号:EP1794164A2
公开(公告)日:2007-06-13
SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS
申请人:Lupin Limited
公开号:EP3490995A1
公开(公告)日:2019-06-05
[EN] COMPOUNDS AS CCRI ANTAGONISTS<br/>[FR] COMPOSES ANTAGONISTES VIS-A-VIS DU RECEPTEUR DE CHIMIOKINE 1 (CCR-1)
申请人:NOVARTIS AG
公开号:WO2005103054A2
公开(公告)日:2005-11-03
A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.
[EN] SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS<br/>[FR] COMPOSÉS DE THIAZOLO-PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE MALT1
申请人:LUPIN LTD
公开号:WO2018020474A1
公开(公告)日:2018-02-01
Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.